The Centre has stopped allocation of antiviral drug Remdesivir to states as the supply of the critical medication has surpassed the demand, Union Minister Mansukh L Mandaviya said on Saturday.
"Now the country has enough #Remdesivir as the supply is much more than the demand. So we have decided to DISCONTINUE the Central Allocation of Remdesivir to States," Mandaviya said in a tweet.
The Minister of State for Chemicals and Fertilisers noted that the supply of the drug, which is being used to treat COVID-19, has been ramped up over ten times from just 33,000 vials a day on April 11, 2021 to 3,50,000 vials per day currently.
The government has also increased the number of plants producing Remdesivir from just 20 to 60 plants within a month, he added.
Besides, the Centre has decided to procure 50 lakh vials of Remdesivir to maintain it as a strategic stock for emergency requirement, Mandaviya said.
"But I have also directed @nppa_india & @CDSCO_INDIA_INF to continuously monitor the availability of Remdesivir in the country," he noted.
In order to improve supply, the government has already waived customs duty on Remdesivir, its raw materials and other components used in making the antiviral drug in order to help augment domestic availability and reduce the cost of the injection.
On April 11, in view of increased demand for Remdesivir, the Centre banned the export of the injection and its active pharmaceutical ingredients (APIs) till the situation improves.
Various drug companies have also cut the prices of Remdesivir injection following intervention of the government.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)